RecruitingNCT07636252

Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

Sponsor

Sheba Medical Center

Enrollment

400 participants

Start Date

Jun 14, 2023

Study Type

OBSERVATIONAL

Conditions

Lung Adenocarcinoma Malignant Pleural Effusions (Mpe)

Summary

This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Non-Interventional Study for people with lung adenocarcinoma and malignant pleural effusions (mpe). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-Interventional Study

Non-Interventional Study, patients go through pleural drainage due to shortness of breath

Locations(1)

Sheba Medical Center

Ramat Gan, Israel, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07636252

Related Trials

SL-28 for Advanced Solid Tumours

NCT073417371 location

Safety and Feasibility of Medical Thoracoscopy Using Single-use Flexible Bronchoscope Versus SemiRigid Pleuroscope in Pleural Effusion

NCT07726784

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT0519883034 locations

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

NCT055178111 location

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT0579716860 locations